Literature DB >> 18028366

An overview of chronic severe asthma.

R Polosa1.   

Abstract

Most asthmatic patients with moderate to severe disease can be satisfactorily managed with a combination of inhaled corticosteroids and beta(2)-agonists. However, there are a few with persistent symptoms, impaired quality of life and excessive health-care utilization, despite this management regimen. These patients often require frequent and even occasionally regular oral corticosteroid use. Chronic, severe asthma is a heterogeneous disease and a systematic diagnostic work-up may help to guide treatment and may even provide information about prognosis. Optimal treatment of chronic severe asthma (CSA) should achieve the best possible asthma control and quality of life with the least dose of systemic corticosteroids. The choice and formulation of therapeutic agent is dictated by the severity of disease and includes conventional, immunosuppressive/immunomodulating and biologic therapies. Unfortunately, current asthma management guidelines offer little contribution to the care of the challenging patient with CSA. In this review, a diagnostic and therapeutic overview of CSA is provided for the benefit of those who have a specific interest in this problematic condition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18028366     DOI: 10.1111/j.1445-5994.2007.01547.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  3 in total

1.  Racial differences in biologic predictors of severe asthma: Data from the Severe Asthma Research Program.

Authors:  Christy Gamble; Evelyn Talbott; Ada Youk; Fernando Holguin; Bruce Pitt; Lori Silveira; Eugene Bleecker; William Busse; William Calhoun; Mario Castro; Kian Fan Chung; Serpil Erzurum; Elliot Israel; Sally Wenzel
Journal:  J Allergy Clin Immunol       Date:  2010-11-04       Impact factor: 10.793

Review 2.  Monoclonal antibodies for the treatment of severe asthma.

Authors:  Salvatore Clienti; Jaymin B Morjaria; Elisa Basile; Riccardo Polosa
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

3.  Weekly low-dose methotrexate for reduction of Global Initiative for Asthma Step 5 treatment in severe refractory asthma: study protocol for a randomized controlled trial.

Authors:  Riccardo Polosa; Salvatore Bellinvia; Massimo Caruso; Rosalia Emma; Angela Alamo; Marek Leszek Kowalski; Christian Domingo
Journal:  Trials       Date:  2014-12-18       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.